<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25811" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nondepolarizing Neuromuscular Blockers</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Clar</surname>
            <given-names>Derek T.</given-names>
          </name>
          <aff>Campbell University SOM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Liu</surname>
            <given-names>Mark</given-names>
          </name>
          <aff>San Antonio Military Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Derek Clar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mark Liu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>18</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25811.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Nondepolarizing neuromuscular blockers (nNMBs) are primarily administered to facilitate endotracheal intubation and serve as adjuvant therapy during the perioperative maintenance of anesthesia and care for critically ill patients. Agents such as rocuronium, vecuronium, pancuronium, atracurium, cisatracurium, and mivacurium are specifically used to enhance airway management and reduce the risk of laryngeal injury during both routine and emergency intubations. These medications also improve mechanical ventilation outcomes in critically ill patients.&#x000a0;nNMBs have several indications approved by the US Food and Drug Administration (FDA), primarily focused on improving airway management, surgical procedures, and mechanical ventilation.</p>
        <p>Administered primarily intravenously, dosing must consider the 95% effective dose (ED95) and ideal body weight to avoid overdose or prolonged paralysis. Adverse reactions, particularly histamine release, can occur, especially with atracurium and mivacurium. This activity outlines the indications, mechanisms of action, administration methods, significant adverse effects, contraindications, adult dosages, monitoring parameters, toxicity, clinical presentation, and drug effect reversal for nNMBs to help healthcare providers optimize patient therapy in anesthesia and other therapeutic contexts.&#x000a0;This activity provides healthcare professionals with the knowledge and tools to enhance patient care, highlighting the essential collaboration among&#x000a0;clinicians for ensuring patient safety during nNMB use.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications and contraindications for using nondepolarizing neuromuscular blockers in various clinical settings, including perioperative and critical care.</p></list-item><list-item><p>Implement standardized protocols for the administration and monitoring of nondepolarizing neuromuscular blockers to ensure safe and effective use in clinical practice.</p></list-item><list-item><p>Select appropriate reversal agents for nondepolarizing neuromuscular blockers based on the specific blocker and clinical scenario to ensure timely recovery of neuromuscular function.</p></list-item><list-item><p>Collaborate with healthcare providers to ensure accurate dosing and maintain resuscitation equipment while administering&#x000a0;nondepolarizing neuromuscular blockers to enhance patient safety.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25811&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25811">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25811.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Nondepolarizing neuromuscular blockers (nNMBs) are used as primary therapy to facilitate endotracheal intubation and as adjuvant therapy for maintaining anesthesia and managing critically ill patients. Common agents, including rocuronium, vecuronium, pancuronium, atracurium, cisatracurium, and mivacurium, help optimize airway management and reduce the risk of laryngeal injury during both routine and emergency intubations.<xref ref-type="bibr" rid="article-25811.r1">[1]</xref>&#x000a0;nNMBs can reduce hoarseness following intubation by lowering the incidence of vocal cord injuries.<xref ref-type="bibr" rid="article-25811.r2">[2]</xref></p>
        <p>Research indicates that nNMBs, when used as adjunctive therapy with intravenous (IV) or inhaled anesthetics, improve mechanical ventilation outcomes in critically ill patients with poor lung compliance, including those receiving perioperative care.<xref ref-type="bibr" rid="article-25811.r3">[3]</xref>&#x000a0;In the perioperative setting, this combination also facilitates access to the thoracic and abdominal cavities by suppressing voluntary and reflex muscle movements.<xref ref-type="bibr" rid="article-25811.r4">[4]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>nNMBs have several indications approved by the US Food and Drug Administration (FDA), primarily focused on improving airway management, surgical procedures, and mechanical ventilation.</p>
        <list list-type="bullet">
          <list-item>
            <p>Endotracheal intubation: Primary use to improve intubation outcomes and facilitate airway management.</p>
          </list-item>
          <list-item>
            <p>Surgical procedures: Adjunctive use with anesthetics to improve surgical field preparation.</p>
          </list-item>
          <list-item>
            <p>Mechanical ventilation: Adjunctive use to improve mechanical ventilation outcomes.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Off-Label&#x000a0;Uses</bold>
</p>
        <p>Currently, there are no off-label uses for nNMBs.</p>
      </sec>
      <sec id="article-25811.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>nNMBs function as competitive antagonists of acetylcholine (ACh) by binding to the alpha subunits of nicotinic receptors on the postsynaptic membrane. Under normal circumstances, the transmission of impulses from the primary motor cortex to motor endplates occurs via ACh release from the presynaptic terminal, diffusion across the synaptic membrane, and binding to nicotinic receptors on the postsynaptic membrane. The binding of the receptor activates its sodium (Na<sup>+</sup>) channel domain, allowing Na<sup>+</sup> influx and depolarizing the motor endplate from a resting membrane potential of &#x02212;100 mV to +40 mV. This depolarization signal then reaches the sarcoplasmic membrane, triggering the release of calcium ions (Ca<sup>2+</sup>) that facilitate muscle contraction.<xref ref-type="bibr" rid="article-25811.r5">[5]</xref>&#x000a0;</p>
        <p>nNMBs play a crucial role in this metabolic process by blocking ACh binding to the alpha subunits on nicotinic receptors, thus maintaining the polarized state of the motor endplate. This mechanism results in muscle paralysis, which is beneficial for patients undergoing perioperative procedures. These agents are classified into 2 subcategories based on their structure and clinical reversal patterns:<xref ref-type="bibr" rid="article-25811.r6">[6]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Steroidal: Rocuronium, vecuronium, and pancuronium&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Benzylisoquinolinium: Atracurium, cisatracurium, and mivacurium</p>
          </list-item>
        </list>
        <p>Although there are slight differences in clinical effects, such as steroidal agents exhibiting greater&#x000a0;vagolytic activity and benzylisoquinolines causing more histamine reactions, both subtypes share the same mechanism of action. However, clinical reversal algorithms have evolved due to the recent introduction of sugammadex.<xref ref-type="bibr" rid="article-25811.r7">[7]</xref></p>
      </sec>
      <sec id="article-25811.s4" sec-type="Administration">
        <title>Administration</title>
        <p>nNMBs are primarily administered via the IV route, with individualized dosing for each agent,&#x000a0;although intramuscular (IM) injections may be feasible for some. The 95% effective dose (ED95) of nNMBs refers to the amount required to achieve 95% twitch suppression in 50% of individuals. For intubation, 1 to 2 times the ED95 dose is typically administered. Weight-based dosing is crucial, as using total body weight can result in overdose, while relying on ideal body weight may be subtherapeutic. To prevent prolonged paralysis, nNMBs are generally dosed based on ideal body weight.<xref ref-type="bibr" rid="article-25811.r8">[8]</xref><xref ref-type="bibr" rid="article-25811.r9">[9]</xref><xref ref-type="bibr" rid="article-25811.r10">[10]</xref></p>
        <p>
<bold>Adult Dosages</bold>
</p>
        <p>The selection of a nondepolarizing NMB depends on factors such as the desired onset speed, duration of action, route of elimination, and potential adverse&#x000a0;effects (see&#x000a0;<bold>Table</bold>&#x000a0;below). For example, rocuronium&#x02019;s rapid onset and short duration make it ideal for endotracheal intubation. In contrast, pancuronium&#x02019;s longer duration and potential to cause significant tachycardia make it less favorable in cases requiring quick reversal due to the risk of prolonged paralysis and postoperative complications.<xref ref-type="bibr" rid="article-25811.r1">[1]</xref></p>
        <table-wrap id="article-25811.table0" position="float" orientation="portrait">
          <caption>
            <title>Table. Dosage Guidelines for Common&#x000a0;Nondepolarizing&#x000a0;Neuromuscular&#x000a0;Blockers&#x000a0;</title>
          </caption>
          <table style="width: 800px; height: 1px;" border="1" cellspacing="1" cellpadding="10">
            <tbody>
              <tr>
                <td style="width: 10px;" rowspan="1" colspan="1">
<bold>Agents</bold>
</td>
                <td style="width: 230px;" rowspan="1" colspan="1">
<bold>Intubation Dosages</bold>
</td>
                <td style="width: 329.388px;" rowspan="1" colspan="1">
<bold>Maintenance Dosages</bold>
</td>
                <td style="width: 151.612px;" rowspan="1" colspan="1">
<bold>Duration of Action</bold>
</td>
              </tr>
              <tr>
                <td style="width: 10px;" rowspan="1" colspan="1">Rocuronium</td>
                <td style="width: 230px;" rowspan="1" colspan="1">IV 0.45-0.90 mg/kg</td>
                <td style="width: 329.388px;" rowspan="1" colspan="1">IV 0.15 mg/kg boluses every 15-20 minutes</td>
                <td style="width: 151.612px;" rowspan="1" colspan="1">45-70 minutes</td>
              </tr>
              <tr>
                <td style="width: 10px;" rowspan="1" colspan="1">Vecuronium</td>
                <td style="width: 230px;" rowspan="1" colspan="1">IV 0.08-0.12 mg/kg</td>
                <td style="width: 329.388px;" rowspan="1" colspan="1">IV 0.04 mg/kg initially, then 0.01 mg/kg every 15-20 minutes</td>
                <td style="width: 151.612px;" rowspan="1" colspan="1">30-40 minutes</td>
              </tr>
              <tr>
                <td style="width: 10px;" rowspan="1" colspan="1">Pancuronium</td>
                <td style="width: 230px;" rowspan="1" colspan="1">IV 0.08-0.12 mg/kg (effective in 2-3 minutes)</td>
                <td style="width: 329.388px;" rowspan="1" colspan="1">IV 0.04 mg/kg initially, then 0.01 mg/kg every 20-40 minutes</td>
                <td style="width: 151.612px;" rowspan="1" colspan="1">&#x02265;180 minutes</td>
              </tr>
              <tr>
                <td style="width: 10px;" rowspan="1" colspan="1">Atracurium</td>
                <td style="width: 230px;" rowspan="1" colspan="1">IV 0.5 mg/kg</td>
                <td style="width: 329.388px;" rowspan="1" colspan="1">Intraoperative (after succinylcholine): IV 0.25 mg/kg initially, then 0.1 mg/kg every 10-20 minutes</td>
                <td style="width: 151.612px;" rowspan="1" colspan="1">&#x02264;30 minutes</td>
              </tr>
              <tr>
                <td style="width: 10px;" rowspan="1" colspan="1">Cisatracurium</td>
                <td style="width: 230px;" rowspan="1" colspan="1">IV 0.1-0.15 mg/kg within 2 minutes before intubation</td>
                <td style="width: 329.388px;" rowspan="1" colspan="1">IV infusion: 1.0-2.0 mcg/kg/min</td>
                <td style="width: 151.612px;" rowspan="1" colspan="1">Variable, generally dose-dependent</td>
              </tr>
              <tr>
                <td style="width: 10px;" rowspan="1" colspan="1">Mivacurium</td>
                <td style="width: 230px;" rowspan="1" colspan="1">IV 0.2 mg/kg</td>
                <td style="width: 329.388px;" rowspan="1" colspan="1">IV infusion: 4-10 mcg/kg/min</td>
                <td style="width: 151.612px;" rowspan="1" colspan="1">Variable, generally short-acting</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Table reference&#x000a0;<xref ref-type="bibr" rid="article-25811.r11">[11]</xref>.</p>
      </sec>
      <sec id="article-25811.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The common adverse reaction to monitor with nNMBs is histamine release. Studies show that benzylisoquinolinium nNMBs (atracurium and mivacurium) have the highest incidence of histamine-induced reactions in the perioperative setting. These reactions can lead to hemodynamic instability (tachycardia and hypotension), bronchospasm, and urticaria.<xref ref-type="bibr" rid="article-25811.r6">[6]</xref>&#x000a0;Slow injection rates and pretreatment with antihistamines can reduce the severity or incidence of these reactions. Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/22125">General Anesthesia for Surgeons</ext-link>," for more information.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>The primary drug interaction to monitor involves the coadministration of nNMBs with inhaled anesthetics (desflurane, sevoflurane, isoflurane, enflurane, halothane, or nitrous oxide). Inhaled anesthetics enhance the effect of nNMBs, requiring dose adjustments to prevent overdose. Failure to reduce the nNMB dose increases the risk of residual neuromuscular blockade and pulmonary complications.<xref ref-type="bibr" rid="article-25811.r1">[1]</xref>&#x000a0;</p>
        <p>Other categories of drug interactions can be classified as either enhancing or inducing resistance to activity:</p>
        <list list-type="bullet">
          <list-item>
            <p>Augmenting agents: Antibiotics (aminoglycosides, clindamycin, and tetracycline), antiarrhythmics (quinidine and calcium channel blockers), dantrolene, ketamine, local anesthetics, and magnesium sulfate.</p>
          </list-item>
          <list-item>
            <p>Resistance-inducing agents: Anticonvulsants (phenytoin, valproic acid, and carbamazepine) and cholinesterase inhibitors (neostigmine and pyridostigmine).</p>
          </list-item>
        </list>
        <p>Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/22125">General Anesthesia for Surgeons</ext-link>," for more information.</p>
      </sec>
      <sec id="article-25811.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p><bold>Contraindications</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Conditions exhibiting resistance: Cerebral palsy, burn injuries, hemiplegia (on the affected side), peripheral nerve injury, severe chronic infections such as botulism or tetanus.</p>
          </list-item>
          <list-item>
            <p>Conditions exhibiting hypersensitivity: Amyotrophic lateral sclerosis (ALS), autoimmune disorders (systemic lupus erythematosus (SLE), polymyositis, and dermatomyositis), Guillain-Barr&#x000e9; syndrome, Duchenne muscular dystrophy, and myasthenia gravis.</p>
          </list-item>
        </list>
        <p>Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/22125">General Anesthesia for Surgeons</ext-link>," for more information.</p>
        <p><bold>Cautions</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypothermia: This condition can prolong neuromuscular blockade by reducing metabolism and elimination.</p>
          </list-item>
          <list-item>
            <p>Respiratory acidosis: This condition&#x000a0;can potentiate neuromuscular blockade and antagonize reversal.</p>
          </list-item>
          <list-item>
            <p>Electrolyte abnormalities: Hypokalemia and hypocalcemia can enhance neuromuscular blockade. Additionally, preeclamptic patients receiving magnesium sulfate may develop hypermagnesemia, which also potentiates the blockade.</p>
          </list-item>
          <list-item>
            <p>Hepatic disease or failure: This condition reduces clearance and increases the volume of distribution.</p>
          </list-item>
          <list-item>
            <p>Renal failure: This condition decreases clearance, although the extent of blockade prolongation varies.</p>
          </list-item>
        </list>
        <p>Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/22125">General Anesthesia for Surgeons</ext-link>," for more information.</p>
      </sec>
      <sec id="article-25811.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Train-of-four (TOF) is&#x000a0;the standard method for monitoring a patient&#x02019;s blockade status during the perioperative and postoperative periods. TOF consists of 4 2-Hz stimulations applied to specific muscle groups to assess the extent of the blockade and, in a prognostic sense, to predict how the patient will respond when maintenance of the blockade is withdrawn. Typically, TOF is performed on the adductor pollicis muscle by stimulating the ulnar nerve, with the desired response being a twitch that indicates muscle contraction. The 4 twitches are quantified, and a normal TOF value is greater than or equal to 1, indicating that the muscle demonstrates improved contraction with each stimulation, such that the fourth twitch is significantly stronger than the first.<xref ref-type="bibr" rid="article-25811.r12">[12]</xref>&#x000a0;</p>
        <p>This reaction indicates that no additional nNMB is needed and that reversal should proceed with a standard dose. However, if the TOF is less than 0.9, there is an increased risk of post-residual blockade and postoperative complications. The primary concern is respiratory distress resulting from the residual blockade of the diaphragm and laryngeal muscles. If TOF is less than 0.7, this would indicate persistent blockade.<xref ref-type="bibr" rid="article-25811.r6">[6]</xref>&#x000a0;In both scenarios, the nNMB should be discontinued, or a higher dose of a reversal agent may be required. Additionally, the patient may need to remain on mechanical ventilation until the blockade sufficiently reverses to allow for spontaneous respiration.<xref ref-type="bibr" rid="article-25811.r11">[11]</xref></p>
      </sec>
      <sec id="article-25811.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of&#x000a0;Overdose</bold>
</p>
        <p>Most nNMBs are metabolized and eliminated through either an ester hydrolysis process conducted by nonspecific esterases at the synaptic cleft or through Hoffman elimination&#x02014;a spontaneous nonenzymatic breakdown that occurs at physiological pH. For atracurium and cisatracurium, Hoffman elimination generates the metabolite laudanosine. If allowed to accumulate, particularly in cases of hepatic failure, this metabolite can lead to central nervous system excitation, potentially resulting in seizure activity.<xref ref-type="bibr" rid="article-25811.r13">[13]</xref>&#x000a0;</p>
        <p>Pancuronium, typically eliminated through deacetylation by hepatocytes, can lead to an increased volume of distribution in patients with cirrhosis or renal failure. Due to pancuronium's&#x000a0;action of inducing high vagal blockade activity, it can lead to hypertension and tachycardia in excess, increasing the risk of ventricular arrhythmias in individuals predisposed to such conditions or those already taking tricyclic antidepressants.<xref ref-type="bibr" rid="article-25811.r14">[14]</xref>&#x000a0;In contrast, both vecuronium and rocuronium are relatively less concerning regarding toxic effects. Vecuronium may potentiate opioid-induced bradycardia in some cases, while rocuronium exhibits only mild vagal blockade effects. Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/22125">General Anesthesia for Surgeons</ext-link>," for more information.</p>
        <p>
<bold>Management of Overdose&#x000a0;</bold>
</p>
        <p><bold> In the event of overdose or perioperative reversal of nNMB activity:&#x000a0;</bold>Initially, all neuromuscular blockers were reversed via acetylcholinesterase inhibitors (neostigmine, edrophonium, and pyridostigmine).<xref ref-type="bibr" rid="article-25811.r15">[15]</xref>&#x000a0;The reversal occurs when these agents block acetylcholinesterase enzymes in the synaptic cleft that normally break down ACh. With these enzymes inhibited, the concentration of ACh at the postsynaptic membrane increases, allowing it to outcompete the antagonists and restore the function of sodium channels, resulting in muscle contraction. Administering neostigmine alone, the most clinically relevant acetylcholinesterase inhibitor, can increase parasympathetic activity, with bronchospasm and laryngeal collapse being the most concerning effects. To mitigate these risks, glycopyrrolate, an antimuscarinic agent, is added to the regimen. Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/22125">General Anesthesia for Surgeons</ext-link>," for more information.</p>
        <p>Sugammadex, a steroidal nNMB binder, is now integrated into reversal protocols due to its effectiveness in reversing nNMB effects with a lower incidence of laryngeal collapse. Sugammadex functions by binding to nNMB molecules in a 1:1 ratio, creating a concentration gradient in the synaptic cleft that facilitates the diffusion of these molecules away from the postsynaptic membrane.<xref ref-type="bibr" rid="article-25811.r6">[6]</xref>&#x000a0;Although&#x000a0;sugammadex was initially developed to reverse steroidal nNMBs, the neostigmine/glycopyrrolate combination remains in use for reversing benzylisoquinolinium nNMBs.<xref ref-type="bibr" rid="article-25811.r15">[15]</xref></p>
      </sec>
      <sec id="article-25811.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>nNMBs are often administered to assist with endotracheal intubations and provide adjuvant therapy during the perioperative maintenance of anesthesia and the care of critically ill patients. These drugs cause paralysis of the muscles, making it difficult for patients to breathe. Therefore, no alert patient should ever receive these agents. To ensure the safety of these drugs, the physician, nurse anesthetist, and nursing staff must collaborate as a team to guarantee safe intubations and achieve the best possible patient outcomes. When administering nondepolarizing agents, resuscitative equipment must be readily available at the bedside for immediate intubation.</p>
        <p>Nurses taking care of patients in the intensive care unit should be familiar with the dosage and potential adverse effects of nNMBs. Additionally, pharmacists should always double-check the drug dosage and possible drug-drug interactions before dispensing it to the nursing staff. Only through open communication and interprofessional teamwork among healthcare providers can patient safety be ensured when using nNMBs.<xref ref-type="bibr" rid="article-25811.r16">[16]</xref></p>
      </sec>
      <sec id="article-25811.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25811&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25811">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25811/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25811">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25811.s11">
        <title>References</title>
        <ref id="article-25811.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Sung</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Factors that affect the onset of action of non-depolarizing neuromuscular blocking agents.</article-title>
            <source>Korean J Anesthesiol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>70</volume>
            <issue>5</issue>
            <fpage>500</fpage>
            <page-range>500-510</page-range>
            <pub-id pub-id-type="pmid">29046769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25811.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lundstr&#x000f8;m</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Duez</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>N&#x000f8;rskov</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Thomsen</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>M&#x000f8;ller</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Strande</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wetterslev</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Avoidance versus use of neuromuscular blocking agents for improving conditions during tracheal intubation or direct laryngoscopy in adults and adolescents.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>May</month>
            <day>17</day>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>CD009237</fpage>
            <pub-id pub-id-type="pmid">28513831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25811.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lieutaud</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Billard</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Khalaf</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Debaene</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Muscle relaxation and increasing doses of propofol improve intubating conditions.</article-title>
            <source>Can J Anaesth</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>121</fpage>
            <page-range>121-6</page-range>
            <pub-id pub-id-type="pmid">12560300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25811.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adam</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Bom</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Feilden</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hutchinson</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Palin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Prosser</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rees</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Rosair</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tarver</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>MQ</given-names>
              </name>
            </person-group>
            <article-title>Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships.</article-title>
            <source>J Med Chem</source>
            <year>2002</year>
            <month>Apr</month>
            <day>25</day>
            <volume>45</volume>
            <issue>9</issue>
            <fpage>1806</fpage>
            <page-range>1806-16</page-range>
            <pub-id pub-id-type="pmid">11960492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25811.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Errando</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Garutti</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mazzinari</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az-Cambronero</surname>
                <given-names>&#x000d3;</given-names>
              </name>
              <name>
                <surname>Bebawy</surname>
                <given-names>JF</given-names>
              </name>
              <collab>Grupo Espa&#x000f1;ol De Estudio Del Bloqueo Neuromuscular</collab>
            </person-group>
            <article-title>Residual neuromuscular blockade in the postanesthesia care unit: observational cross-sectional study of a multicenter cohort.</article-title>
            <source>Minerva Anestesiol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>82</volume>
            <issue>12</issue>
            <fpage>1267</fpage>
            <page-range>1267-1277</page-range>
            <pub-id pub-id-type="pmid">27232277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25811.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zafirova</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Dalton</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Neuromuscular blockers and reversal agents and their impact on anesthesia practice.</article-title>
            <source>Best Pract Res Clin Anaesthesiol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>203</fpage>
            <page-range>203-211</page-range>
            <pub-id pub-id-type="pmid">30322460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25811.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zoremba</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sch&#x000e4;lte</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bruells</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>P&#x000fc;hringer</surname>
                <given-names>FK</given-names>
              </name>
            </person-group>
            <article-title>[Update on muscle relaxation : What comes after succinylcholine, rocuronium and sugammadex?].</article-title>
            <source>Anaesthesist</source>
            <year>2017</year>
            <month>May</month>
            <volume>66</volume>
            <issue>5</issue>
            <fpage>353</fpage>
            <page-range>353-359</page-range>
            <pub-id pub-id-type="pmid">28289767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25811.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ingrande</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lemmens</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Dose adjustment of anaesthetics in the morbidly obese.</article-title>
            <source>Br J Anaesth</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>105 Suppl 1</volume>
            <fpage>i16</fpage>
            <page-range>i16-23</page-range>
            <pub-id pub-id-type="pmid">21148651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25811.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agoston</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vandenbrom</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Wierda</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of neuromuscular blocking drugs.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1992</year>
            <month>Feb</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>94</fpage>
            <page-range>94-115</page-range>
            <pub-id pub-id-type="pmid">1551294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25811.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prielipp</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Coursin</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Applied pharmacology of common neuromuscular blocking agents in critical care.</article-title>
            <source>New Horiz</source>
            <year>1994</year>
            <month>Feb</month>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-47</page-range>
            <pub-id pub-id-type="pmid">7922428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25811.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beutler</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Gimlich</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Urman</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Investigation of intraoperative&#x000a0;dosing patterns of neuromuscular blocking agents.</article-title>
            <source>J Clin Monit Comput</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>455</fpage>
            <page-range>455-462</page-range>
            <pub-id pub-id-type="pmid">30094585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25811.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naguib</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brull</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kopman</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>F&#x000fc;lesdi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Arkes</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Elstein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Todd</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>KB</given-names>
              </name>
            </person-group>
            <article-title>Consensus Statement on Perioperative Use of Neuromuscular Monitoring.</article-title>
            <source>Anesth Analg</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>127</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <page-range>71-80</page-range>
            <pub-id pub-id-type="pmid">29200077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25811.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakuraba</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hosokawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kaku</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kuwana</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Laudanosine has no effects on respiratory activity but induces non-respiratory excitement activity in isolated brainstem-spinal cord preparation of neonatal rats.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2010</year>
            <volume>669</volume>
            <fpage>177</fpage>
            <page-range>177-80</page-range>
            <pub-id pub-id-type="pmid">20217344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25811.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kandukuri</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Tahmindjis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hildreth</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Effect of anaesthetic and choice of neuromuscular blocker on vagal control of heart rate under laboratory animal experimental conditions.</article-title>
            <source>Lab Anim</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>52</volume>
            <issue>3</issue>
            <fpage>280</fpage>
            <page-range>280-291</page-range>
            <pub-id pub-id-type="pmid">28862524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25811.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bulka</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Terekhov</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Dmochowski</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Ehrenfeld</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Nondepolarizing Neuromuscular Blocking Agents, Reversal, and Risk of Postoperative Pneumonia.</article-title>
            <source>Anesthesiology</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>125</volume>
            <issue>4</issue>
            <fpage>647</fpage>
            <page-range>647-55</page-range>
            <pub-id pub-id-type="pmid">27496656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25811.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Groth</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Acquisto</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Khadem</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Current practices and safety of medication use during rapid sequence intubation.</article-title>
            <source>J Crit Care</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>45</volume>
            <fpage>65</fpage>
            <page-range>65-70</page-range>
            <pub-id pub-id-type="pmid">29413725</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
